PD-1 signaling is essential for the early accumulation of HBV-specific CD8+ T cells during HBV infection
Xiaoqing ZengiD, Wen PaniD, Ziwei LiiD, Zhaoli LiuiD, Hongming HuangiD, Xuecheng YangiD, Kathrin SutteriD, Mengji LuiD, Ulf DittmeriD, Gennadiy ZelinskyyiD, Xin ZhengiD, Dongliang YangiD, Patrick T.F. KennedyiD, Yanqin DuiD, Jia LiuiD
Abstract
Background & AimsProgrammed cell death Protein 1(PD-1) is one of the key inhibitory receptors that regulates CD8 T cell exhaustion during chronic viral infection. However, the role of PD-1 in modulating effector T cell differentiation and function during early phase of hepatitis B virus (HBV) infection remains poorly defined. MethodsUsing adoptive transfer of wild-type or PD-1 KO HBV-specific TCR transgenic (C93-TCRtg) CD8 T cells, flow cytometry, and transcriptome sequencing, we systematically profiled early PD-1 dynamics in splenic and intrahepatic T cells and evaluated how PD-1 deficiency shapes anti-HBV T cell responses in acute self-resolving (AR) and chronic (CH) HBV mouse models. ResultsAcute HBV infection induced sustained PD-1 upregulation on intrahepatic/splenic CD8 T cells, which predominantly exhibited an effector phenotype. PD-1 cells displayed enhanced proliferation, cytotoxicity, and effector cytokine production compared to PD-1- counterparts. Adoptive transfer of PD-1 KO C93-TCRtg CD8 T cells resulted in significantly impaired early expansion in both spleen and liver during acute infection, accompanied by reduced granzyme B expression while maintaining IFN-{gamma}, TNF-, or IL-2 production. Transcriptomic analysis revealed that PD-1 deficiency was associated with the upregulation of apoptosis gene signatures. In chronic HBV infection, PD-1 KO cells failed to expand long-term and exhibited exacerbated exhaustion evidenced by a loss of IFN-{gamma} production. ConclusionsPD-1 is essential for the early expansion and survival of HBV-specific CD8 T cells during acute infection and does not suppress their effector cytokine function. Its absence impairs proliferation and promotes exhaustion of HBV-specific CD8 T cell in chronic infections. Impact and implicationsOur study redefines PD-1s role in acute HBV infection. Rather than merely constraining effector function, PD-1 is essential for the early expansion and survival of HBV-specific CD8+ T cells, acting as a safeguard against activation-induced apoptosis. The context-dependent functions position PD-1 as a critical rheostat calibrating the magnitude and quality of the antiviral CD8+ T cell response, with significant implications for immunotherapeutic strategies targeting this pathway in hepatitis B.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- PD-L1 upregulation by IFN-α/γ-mediated Stat1 suppresses anti-HBV T cell response
LanLan Liu, Junwei Hou, … Songdong Meng·PLoS ONEPeer-reviewed·Jul 6, 2020
- CD8 T cells with classical and NK-like cytotoxic gene expression programs mediate control of HBV replication and functional cure
Elias Isaac Lattouf, Martin Feuerherd, … Georg M. Lauer·bioRxiv·Jun 29, 2026
- Enhancing HBV-specific T cell responses through a combination of epigenetic modulation and immune checkpoint inhibition
Melanie Urbanek‐Quaing, Yin-Han Chou, … Markus Cornberg·HepatologyPeer-reviewed·Dec 19, 2024
- AAV-HBV mouse model replicates immune exhaustion patterns of chronic HBV patients at single-cell level
N. Conceicao-Neto, Q. Han, … E. Van Gulck·bioRxiv·Aug 7, 2023
- Clinical cure of chronic hepatitis B is dependent on activation and perpetuation of robust CD4+ T cell responses
Jillian M. Jespersen, Lia Avanesyan, … Jody L. Baron·bioRxiv·Sep 29, 2025
- HDAC1 controls the generation and maintenance of effector-like CD8+ T cells during chronic viral infection
Ramona Rîca, Monika Waldherr, … Shinya Sakaguchi·The Journal of Experimental MedicinePeer-reviewed·May 21, 2025